Buscar
Congreso SOLACI
HomeCoronary diseaseDrug-eluting stents

Drug-eluting stents

Ver Categoría

Coronary disease

DESSOLVE III: Xience vs. MiStent

The MiStent device is made of cobalt-chromium, with struts of up to 64 µm thick. It is coated...
solaci -
Ver más
Drug-eluting stents

Promising Outcomes of Overlapping Stents in Patients Undergoing Bioresorbable Scaffold (BRS) Implantation

Courtesy of Dr. Guillermo Migliaro. In regular clinical practice, overlapping stents are reported in up to 30% of...
solaci -
Ver más
Antiplatelet

Dual antiaggregation time and death by bleeding

Despite the fact that some randomized studies and meta-analyzis have suggested prolonged dual antiaggregation could be associated...
solaci -
Ver más
Coronary disease

Bioresorbable scaffolds with drug-eluting stents: do they entail a higher thrombosis risk?

Courtesy of Dr. Leiva. Bioresorbable scaffolds with drug-eluting stents (bioresorbable vascular scaffolds, BVS) have been added to the...
solaci -
Ver más
ACC 2017 HIGHLIGHTS

ABSORB III: More Events with Absorb Than With Xience at Two Years

The two year outcomes of ABSORB III, presented at the scientific sessions of the American College of...
solaci -
Ver más
Coronary disease

Biolimus and Everolimus Eluting Stents in Coronary Artery Disease: Similar Safety?

Courtesy of Dr. Guillermo Migliaro. Events such as very late stent thrombosis and restenosis after first generation DES...
solaci -
Ver más
Chronic Ischemic cardiopathy

Why We Should Use IVUS in Complex Coronary Lesions

Courtesy of Dr. Carlos Fava. Drug eluting stents (DES) have shown benefits in terms of restenosis vs. conventional...
solaci -
Ver más
Coronary disease

Zotarolimus with Durable Polymer vs. Biolimus with Biodegradable Polymer

The present work compared the safety and efficacy of the permanent polymer zotarolimus eluting stent vs. the...
solaci -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Dr. Omar Tupayachi - 0
Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Dr. Juan Manuel Pérez - 0
Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Dr. Juan Manuel Pérez - 0
Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Noticias Institucionales

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with...

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

solaci - 0
The Latin American Society of Interventional Cardiology invites you to participate in a new virtual scientific event titled “Pulmonary Embolism (PE) in 2025: Risk...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad